246 related articles for article (PubMed ID: 33495313)
1. Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells.
Pan W; Zhang Z; Kimball H; Qu F; Berlind K; Stopsack KH; Lee GM; Choueiri TK; Kantoff PW
Clin Cancer Res; 2021 Apr; 27(7):2087-2099. PubMed ID: 33495313
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone acetate in the treatment of prostate cancer.
Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S
Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
[TBL] [Abstract][Full Text] [Related]
3. Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells.
Ianculescu I; Wu DY; Siegmund KD; Stallcup MR
J Biol Chem; 2012 Feb; 287(6):4000-13. PubMed ID: 22174411
[TBL] [Abstract][Full Text] [Related]
4. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer.
Mortezavi A; Salemi S; Kranzbühler B; Gross O; Sulser T; Simon HU; Eberli D
World J Urol; 2019 Feb; 37(2):351-358. PubMed ID: 29951789
[TBL] [Abstract][Full Text] [Related]
7. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.
Modena A; Ciccarese C; Fantinel E; Bimbatti D; Tortora G; Massari F
Expert Rev Anticancer Ther; 2015; 15(9):1037-48. PubMed ID: 26134919
[TBL] [Abstract][Full Text] [Related]
8. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Boissier E; Loriot Y; Vignot S; Massard C
Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-4 activates androgen receptor through CBP/p300.
Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
[TBL] [Abstract][Full Text] [Related]
11. Induction of chemoresistance by all-trans retinoic acid via a noncanonical signaling in multiple myeloma cells.
Liu Z; Li T; Jiang K; Huang Q; Chen Y; Qian F
PLoS One; 2014; 9(1):e85571. PubMed ID: 24416428
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of p300-mediated transcription by the kinase MEKK1.
See RH; Calvo D; Shi Y; Kawa H; Luke MP; Yuan Z; Shi Y
J Biol Chem; 2001 May; 276(19):16310-7. PubMed ID: 11278389
[TBL] [Abstract][Full Text] [Related]
13. The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB.
Geiger TR; Sharma N; Kim YM; Nyborg JK
Mol Cell Biol; 2008 Feb; 28(4):1383-92. PubMed ID: 18070920
[TBL] [Abstract][Full Text] [Related]
14. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
[TBL] [Abstract][Full Text] [Related]
15. [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy].
Merseburger AS; Rüssel C; Belz H; Spiegelhalder P; Feyerabend S; Tran N; Kruetzfeldt K; Baurecht W; Bögemann M
Aktuelle Urol; 2020 Dec; 51(6):562-571. PubMed ID: 32268436
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
Sunkel B; Wu D; Chen Z; Wang CM; Liu X; Ye Z; Horning AM; Liu J; Mahalingam D; Lopez-Nicora H; Lin CL; Goodfellow PJ; Clinton SK; Jin VX; Chen CL; Huang TH; Wang Q
Nucleic Acids Res; 2016 May; 44(9):4105-22. PubMed ID: 26743006
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
Yamada Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S
BMC Res Notes; 2016 Oct; 9(1):471. PubMed ID: 27756383
[TBL] [Abstract][Full Text] [Related]
18. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
19. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
20. Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients.
Gordevičius J; Kriščiūnas A; Groot DE; Yip SM; Susic M; Kwan A; Kustra R; Joshua AM; Chi KN; Petronis A; Oh G
Clin Cancer Res; 2018 Jul; 24(14):3317-3324. PubMed ID: 29615462
[No Abstract] [Full Text] [Related]
[Next] [New Search]
